SCHEMBL289359

SCHEMBL289359

CON(C)C(=O)c1cc(OCc2ccccc2)c(-c2ccc(F)cc2)c(OCc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
PTGER1 P34995 3/20 0.47
APP P05067 1/20 0.46
BRD4 O60885 1/20 0.44
NPC1 O15118 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SMPD1 P17405 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MRGPRX4 Q96LA9 2/20 0.42
SSTR5 P35346 1/20 0.42
EGFR P00533 1/20 0.42
GPBAR1 Q8TDU6 1/20 0.42
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30807979 0.82 APP (0.52) APPBRD4NPC1HPGDRAB9A
SCHEMBL17191961 0.81 APP (0.47) PTGER1APPBRD4NPC1HPGD
SCHEMBL5604787 0.81 BRD4 (0.53) KMT2APTGER1APPBRD4NPC1
SCHEMBL13076466 0.80 BRD4 (0.56) KMT2APTGER1BRD4NPC1RAB9A
SCHEMBL290026 0.80 PTGER1 (0.52) KMT2APTGER1NPC1RAB9ASMN1; SMN2
SCHEMBL4480514 0.79 APP (0.52) KMT2AAPPNPC1HPGDSMN1; SMN2
SCHEMBL31371784 0.79 FFAR4 (0.53) KMT2AAPPNPC1LMNAMAPT
SCHEMBL16056330 0.77 MRGPRX4 (0.50) PTGER1SMN1; SMN2LMNAMRGPRX4SSTR5
SCHEMBL5604221 0.77 BRD4 (0.54) KMT2AAPPBRD4NPC1HPGD
SCHEMBL2290346 0.75 TRPM8 (0.55) KMT2APTGER1APPNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427465-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS Merck Sharp & Dohme Corp. (US) 2012-03-14 EP disclosed
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. 2012-02-16 US disclosed
WO-2010129729-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041012-A1 SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS SSTR5, SSTR2, GPR119 KMT2A 2457/4885PTGER1 716/4885APP 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.